Abstract
Changes in DNA methylation patterns is a prominent characteristic of human tumors. Tumor cells display reduced levels of genomic DNA methylation and site-specific CpG island hypermethylation. Methylation of CpG dinucleotides is catalyzed by the enzyme family of DNA methyltransferases (DNMTs). In this review, the role of DNA methylation and DNMTs as key determinants of carcinogenesis is further elucidated. The chromatin modifying proteins that are known to interact with DNMTs are also described. Finally, the role of DNMTs as potential therapeutic targets is addressed.
Keywords: Biomarkers, cancer, chromatin modification, CpG methylation, DNMTs, epigenetic therapy, oncogenes, tumor suppressor genes, DNA cytosine-5 methyltransferases, DNA methyltransferases, Aberrant methylation, histone proteins, histone acetyltransferases (HATs), histone methyltransferases, retinoblastoma-associated histone-binding proteins, lymphoid-specific helicase, estrogenreceptor, restriction landmark genomic scanning, RLGS, methylation-specific PCR, heterochromatin, 5-aza-2'-deoxycytidine, Polycomb Repressive Complex 2, PRC2, 5-azacytidine (Vidaza), 5-aza-2'-deoxycytidine (Decitabine), myelodysplastic syndromes, MDS
Current Genomics
Title: Cytosine Methyltransferases as Tumor Markers
Volume: 11 Issue: 8
Author(s): Athanasia Pavlopoulou and Sophia Kossida
Affiliation:
Keywords: Biomarkers, cancer, chromatin modification, CpG methylation, DNMTs, epigenetic therapy, oncogenes, tumor suppressor genes, DNA cytosine-5 methyltransferases, DNA methyltransferases, Aberrant methylation, histone proteins, histone acetyltransferases (HATs), histone methyltransferases, retinoblastoma-associated histone-binding proteins, lymphoid-specific helicase, estrogenreceptor, restriction landmark genomic scanning, RLGS, methylation-specific PCR, heterochromatin, 5-aza-2'-deoxycytidine, Polycomb Repressive Complex 2, PRC2, 5-azacytidine (Vidaza), 5-aza-2'-deoxycytidine (Decitabine), myelodysplastic syndromes, MDS
Abstract: Changes in DNA methylation patterns is a prominent characteristic of human tumors. Tumor cells display reduced levels of genomic DNA methylation and site-specific CpG island hypermethylation. Methylation of CpG dinucleotides is catalyzed by the enzyme family of DNA methyltransferases (DNMTs). In this review, the role of DNA methylation and DNMTs as key determinants of carcinogenesis is further elucidated. The chromatin modifying proteins that are known to interact with DNMTs are also described. Finally, the role of DNMTs as potential therapeutic targets is addressed.
Export Options
About this article
Cite this article as:
Pavlopoulou Athanasia and Kossida Sophia, Cytosine Methyltransferases as Tumor Markers, Current Genomics 2010; 11 (8) . https://dx.doi.org/10.2174/138920210793360916
DOI https://dx.doi.org/10.2174/138920210793360916 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Current Pharmaceutical Design subject Index To Volume 3
Current Drug Targets HuR as Therapeutic Target in Cancer: What the Future Holds
Current Medicinal Chemistry Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Current Drug Targets Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Magnetic and Gold-Coated Magnetic Iron Oxide Nanoparticles as Detection Tools: Preparation, Characterization, and Biosensing Applications
Current Nanoscience The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology